horizon therapeutics south san francisco

For more information, please visit and follow on Twitter and LinkedIn.ĪlloCAR T™ is a trademark of Allogene Therapeutics, Inc. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. and South San Francisco in support of the LGBTQ+ community. and celebrated together at our offices in Rockville, Md.

Upon registering for the conference call, you will receive a personal PIN to access the call.Īllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. At Horizon, we believe science and compassion must work together to. If you would like the option to ask a question on the conference call, please use this link to register. A replay will be available on the Company's website for approximately 30 days. The listen-only webcast will be made available on the Company's website at under the Investors tab in the News and Events section.

The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2023 financial results on Wednesday, August 2, 2023, after the close of the market.

SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - Allogene Therapeutics, Inc.

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET.

Horizon therapeutics south san francisco